Partnerships, Licensing, Investments and M&A Deals and Trends for February 2016 in Pharmaceuticals

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1000
Buy Report

Published: April 01, 2016 Report Code: GDPH0493MD-ST

Select Item

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for February 2016 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in February 2016. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry. Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

• Analysis of the market trends for the pharmaceutical industry in the global arena.

• Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

• Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

• Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

• Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

• Analysis of partnership and licensing deals based on clinical stage of development of products.

• Summary of the pharmaceutical deals globally in the six months.

• Information on the top deals happened in the pharmaceutical industry.

• Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

• League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to Buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1Table of Contents

1Table of Contents2

1.1List of Tables7

1.2List of Figures10

2Pharmaceuticals & Healthcare, Global, Deal Summary13

2.1Pharmaceuticals & Healthcare, Global, Deal Analysis, February 201613

2.2Pharmaceuticals & Healthcare, Global, Major Deals, February 201615

2.2.1Mylan to Acquire Meda for USD9.9 Billion15

2.2.2GTCR to Form Joint Venture with Ed Fiorentino17

2.2.3Baxalta Enters into Agreement with Precision Biosciences17

2.2.4McKesson to Acquire Vantage Oncology and Biologics for USD1.2 Billion18

2.2.5Ipsen Enters into Licensing Agreement with Exelixis18

2.3Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, February 201620

2.4Pharmaceuticals & Healthcare, Global, by Type, Deal Values, February 201621

3Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type22

3.1Pharmaceuticals & Healthcare, Global, M&A, February 201622

3.1.1Top M&A Deals in February 201623

3.1.2Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, September 2015 – February 201624

3.2Pharmaceuticals & Healthcare, Global, Equity Offering Deals, February 201626

3.2.1Top Equity Offering Deals in February 201627

3.2.2Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, September 2015 – February 201628

3.3Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, February 201630

3.3.1Top PE/VC Deals in February 201631

3.3.2Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, February 201632

3.3.3Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, February 201634

3.3.4Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, September 2015–February 201636

3.3.5Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2015–February 201637

4Pharmaceuticals & Healthcare, Global, Partnership Deals, February 201638

4.1Pharmaceuticals & Healthcare, Global, Partnership Deals, February 201638

4.2Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, September 2015 – February 201640

4.3Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), February 201642

4.3.1Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, February 201643

4.4Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), September 2015 – February 201644

4.5Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, September 2015 – February 201646

4.6Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), September 2015 – February 201647

4.7Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2015 – February 201649

5Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 201651

5.1Pharmaceuticals & Healthcare, Global, Licensing Agreements, February 201651

5.2Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), February 201653

5.3Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), September 2015 – February 201655

5.4Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), September 2015 – February 201657

5.5Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), September 2015 – February 201659

5.6Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), September 2015 – February 201662

5.6.1Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, February 201663

5.6.2Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, February 201664

5.6.3Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, February 201664

6Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area65

6.1Pharmaceuticals & Healthcare, Global, Oncology Deals, February 201665

6.1.1Oncology – Deals of the Month67

6.2Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, February 201669

6.2.1Central Nervous System – Deals of the Month71

6.3Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, February 201672

6.3.1Infectious Diseases – Deals of the Month74

6.4Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, February 201675

6.4.1Cardiovascular – Deals of the Month77

6.5Pharmaceuticals & Healthcare, Global, Immunology Deals, February 201678

6.5.1Immunology – Deals of the Month79

6.6Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, February 201680

6.6.1Gastrointestinal – Deal of the Month82

6.7Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, February 201683

6.7.1Metabolic Disorders – Deal of the Month84

7Deal Summary by Geography85

7.1Pharmaceuticals & Healthcare, North America Deals, February 201685

7.1.1North America – Deals of the Month87

7.2Pharmaceuticals & Healthcare, Europe, Deals, February 201689

7.2.1Europe – Deals of the Month91

7.3Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, February 201693

7.3.1Asia-Pacific – Deals of the Month94

7.4Pharmaceuticals & Healthcare, Rest of the World, Deals, February 201696

7.4.1Rest of the World – Deals of the Month97

8Pharmaceuticals & Healthcare, Global, Top Financial Advisors98

8.1Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, September 2015 – February 201698

8.2Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, September 2015 – February 2016100

9Further Information102

9.1Methodology102

9.2About GlobalData103

9.3Disclosure information103

9.4Disclaimer104

Table

1.1List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201614

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, February 201615

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), February 201621

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201623

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, February 201623

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2015 – February 201625

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201627

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, February 201627

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201629

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201631

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, February 201631

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, September 2015 – February 201633

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), February 201635

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2015 – February 201637

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, September 2015 – February 201637

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2015 – February 201639

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2015 – February 201641

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 – February 201643

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), February 201643

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 – February 201645

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2015 – February 201648

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), September 2015 – February 201650

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201652

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 – February 201654

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2015 – February 201656

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), February 201658

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2015 – February 201661

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), February 201663

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, February 201663

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, February 201664

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, February 201664

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201666

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201670

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201673

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201676

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201679

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201681

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201684

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201686

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201690

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201694

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201697

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2015 – February 201699

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2015 – February 2016101

Figures

1.2List of Figures

Figure 1:Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), September 2015 – February 201613

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), February 201620

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), February 201621

Figure 4:Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), September 2015 – February 201622

Figure 5:Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2015 – February 201624

Figure 6:Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), September 2015 – February 201626

Figure 7:Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2015 – February 201628

Figure 8:Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), September 2015 – February 201630

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, September 2015 – February 201632

Figure 10:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), February 201634

Figure 11:Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), February 201635

Figure 12:Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), September 2015 – February 201636

Figure 13:Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), September 2015 – February 201638

Figure 14:Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2015 – February 201640

Figure 15:Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 – February 201642

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 – February 201644

Figure 17:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2015 – February 201646

Figure 18:Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, September 2015 – February 201647

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), September 2015 – February 201649

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), September 2015 – February 201651

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 – February 201653

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), September 2015 – February 201655

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), September 2015 – February 201657

Figure 24:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, September 2015 – February 201659

Figure 25:Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), September 2015 – February 201660

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), February 201662

Figure 27:Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), September 2015 – February 201665

Figure 28:Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), September 2015 – February 201669

Figure 29:Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), September 2015 – February 201672

Figure 30:Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), September 2015 – February 201675

Figure 31:Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), September 2015 – February 201678

Figure 32:Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201680

Figure 33:Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), September 2015 – February 201683

Figure 34:Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), September 2015 – February 201685

Figure 35:Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), September 2015 – February 201689

Figure 36:Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), September 2015 – February 201693

Figure 37:Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), September 2015 – February 201696

Figure 38:Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), September 2015 – February 201698

Figure 39:Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), September 2015 – February 2016100

Frequently asked questions

Partnerships, Licensing, Investments and M&A Deals and Trends for February 2016 in Pharmaceuticals standard reports
Currency USD
$1,000

Can be used by individual purchaser only

Most Popular
$2,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$3,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Partnerships, Licensing, Investments and M&A Deals and Trends for February 2016 in Pharmaceuticals in real time.

  • Access a live Partnerships, Licensing, Investments and M&A Deals and Trends for February 2016 in Pharmaceuticals dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more